Vakzine Projekt Management (VPM), a Germany-based vaccine development and consultancy spinout from Helmholtz Centre for Infection Research (HZI), was acquired by immunobiological drug firm Serum Institute of India for an undisclosed sum today.
The all-cash deal provides an exit to the research centre’s tech transfer partner, Ascenion. Prior to the transaction, 90% of VPM’s equity was held by Ascenion, university sponsor association Friends of the HZI, and pharmaceutical consultancy Corvay.
Friends of the HZI continues to hold a 10% stake…
